Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study

Montaudié, Henri; Albert-Sabonnadière, Christine; Acquacalda, Emilie; Fontas, Éric; Danré, Agnès; Roux, Christian; Jp, Ortonne; Lacour, Jean‐Philippe; Euller-Ziegler, L.; Passeron, Thierry

doi:10.1111/jdv.12255

Cited by 23 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hs‐CRP as a marker of systemic inflammation has been shown to decrease with psoriasis treatment, as observed here with secukinumab and etanercept …”

Section: Discussionsupporting

confidence: 66%

“…In this context, it is of high interest to examine the metabolic and liver effects of systemic psoriasis treatments. Markers of systemic inflammation decrease with a range of systemic treatments for psoriasis and other inflammatory conditions; however, impact on metabolic and liver parameters, including weight, is more diverse . Different metabolic effects have been described for existing treatment options.…”

Section: Introductionmentioning

confidence: 99%

“…Markers of systemic inflammation decrease with a range of systemic treatments for psoriasis and other inflammatory conditions; however, impact on metabolic and liver parameters, including weight, is more diverse. 17 Different metabolic effects have been described for existing treatment options. Anti-tumour necrosis factoralpha (anti-TNF-alpha) biologic agents may be associated with weight gain in psoriasis and psoriatic arthritis (PsA) patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients

Gerdes

Pinter

Papavassilis

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Psoriasis is associated with metabolic, liver and cardiovascular comorbidity. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, has shown significant and sustained efficacy in the treatment of moderate to severe psoriasis. Objectives This was an exploratory post hoc analysis of pooled data from three phase 3 studies in plaque psoriasis patient populations. The objective was to show the course of metabolic and liver parameters under secukinumab, etanercept or placebo treatment over time. A further objective was to assess the impact of selected comorbidities and metabolic characteristics on high‐sensitivity C‐reactive protein (hs‐CRP), as a surrogate marker of systemic inflammation. Methods Data from the phase 3 randomized controlled trials [FIXTURE (NCT01358578), ERASURE (NCT01365455) and SCULPTURE (NCT01406938); n = 3010] were included in this analysis. Patients were treated with secukinumab 150 mg or 300 mg, placebo or etanercept 50 mg (FIXTURE only) as active comparator. A set of metabolic and liver parameters was longitudinally assessed over 52 weeks. Multivariate regression analyses assessed the impact of selected comorbidities and metabolic characteristics on hs‐CRP levels at baseline and under treatment. Results Secukinumab treatment reduced hs‐CRP levels. Body weight and uric acid levels tended to decrease over 52 weeks with secukinumab. Secukinumab showed a neutral effect on fasting plasma glucose, lipid parameters and liver enzymes. Psoriatic arthritis, metabolic syndrome, obesity, impaired glucose metabolism, and hyperuricemia were each associated with increased hs‐CRP levels at baseline. Concomitant obesity attenuated the decline in hs‐CRP under treatment. Conclusions These analyses suggest neutral to favourable long‐term trends in metabolic and liver parameters under secukinumab treatment. Metabolic comorbidities were associated with increased hs‐CRP levels, reflecting the role of systemic inflammatory processes in their pathophysiology.

show abstract

“…Hs‐CRP as a marker of systemic inflammation has been shown to decrease with psoriasis treatment, as observed here with secukinumab and etanercept …”

Section: Discussionsupporting

confidence: 66%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients

Gerdes

Pinter

Papavassilis

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The systemic inflammation may increase the risk of other chronic diseases as associations with cardiovascular disease, type 2 diabetes, obesity and metabolic syndrome have been established. Growing literature on comorbidity risks in psoriasis [15] and increased understanding of the immunopathology of psoriatic inflammation has moreover redefined psoriasis as a chronic systemic inflammation, especially in patients with moderate-to-severe course of disease [16,17]. Early detection and appropriate informahealthcare.com treatment of these comorbid diseases are important for preventing progression to more advanced stages.…”

mentioning

confidence: 98%

Quality of life in psoriasis patients

Augustin

Radtke

2014

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Patient-reported outcomes are major components of decision making in clinical research, reimbursement, health policy and health care for psoriasis. The most important construct in patient-reported outcomes is health-related quality of life (HRQoL) which encompasses the individual's well-being with respect to health. HRQoL cannot directly be measured but is assessed in single dimensions, especially physical, emotional, social and functional aspects. For this, disease- and condition-specific instruments are used. Psoriasis is a chronic inflammatory disease affecting the skin as well as other tissues and organ systems. Patients suffer from a large scale of impairments, for example, physical symptoms, stigmatization and embarrassment, psychological strain and disabilities in profession. Improvement of HRQoL is a major objective of disease management. Current knowledge on determinants of HRQoL and the treatments available increase QoL in clinical care.

show abstract

“…Psoriasis is a chronic inflammatory skin disease. Experimental and clinical data indicate that chronic inflammation is an important risk factor of CVD and accelerated atherosclerosis [26]. Inflammatory markers such as C-reactive protein (CRP) levels are increased in patients with psoriasis compared with controls [6].…”

Section: Discussionmentioning

confidence: 99%

Growth Arrest‐Specific 6 and Cardiometabolic Risk Factors in Patients with Psoriasis

Sünbül

Cagman

Gerin³

et al. 2015

Cardiovascular Therapeutics

View full text Add to dashboard Cite

SUMMARYObjectives: An increased risk for cardiovascular disease with psoriasis has been reported. Growth Arrest-Specific 6 (GAS6) amplifies pro-inflammatory endothelial cell activation via TAM receptors. However, it also inhibits inflammation by multiple mechanisms including phagocytosis. The objective of this study was to investigate whether plasma GAS6 levels are associated with conventional cardiometabolic (CM) risk factors in patients with psoriasis. Methods: Forty patients diagnosed with psoriasis (22 male, mean age: 43.3 AE 13.8 years) and 40 age-/sex-matched healthy controls (22 male, mean age: 39.3 AE 8.9 years) were included in the study. CM risk factors (hypertension, hyperlipidemia, diabetes mellitus, and cigarette smoking) were identified. GAS6 levels were measured by ELISA. Results: There were no significant differences between the plasma GAS6 levels of patients with psoriasis compared to the control group (6.6 AE 2.0 ng/mL, 7.6 AE 2.8 ng/mL, respectively, P > 0.05). However, GAS6 levels of patients with psoriasis having a smoking history (n = 11) were significantly lower than both patients with psoriasis who had no smoking history (n = 29) and controls (5.5 AE 1.7 ng/mL, 6.9 AE 1.9 ng/mL, 7.6 AE 2.8 ng/mL, respectively, P < 0.05). Similarly, psoriasis patients with at least one CM risk factor showed lower GAS6 levels compared to subjects without any CM risk factor (5.7 AE 1.7 ng/mL, 7.3 AE 2.0 ng/mL, P < 0.01). There was no correlation between the GAS6 level, disease duration or PASI score (r = 0.150, À0.150, and P = 0.310, 0.398, respectively). Conclusions: This pilot study provides the first evidence in humans for an association between low plasma GAS6 levels and conventional risk factors in psoriasis. Further large scale, prospective studies are needed to confirm these results.

show abstract

Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study

Cited by 23 publications

References 24 publications

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients

Quality of life in psoriasis patients

Growth Arrest‐Specific 6 and Cardiometabolic Risk Factors in Patients with Psoriasis

Contact Info

Product

Resources

About